More on SHPGY

- Summary
- Chart
- Profile
- Historical

Data

- Earnings
- Ratings (6.0 Score)
- Holders

Financials

Income Statement
Balance Sheet
Cash Flow Statement

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

SHPGY Cash Flow Statement

Click line-items for a historical chart and %
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization 877.8M
Share based compensation 269.6M
Gain on sale of non-current investments
Other
Movement in deferred taxes -546.9M
Equity in earnings of equity method investees
Loss/(gain) on sale of product rights
Changes in operating assets and liabilities:
Increase in accounts receivable -411.2M
Increase in sales deduction accrual 108.2M
Increase in inventory -228M
Increase in prepayments and other assets -66.4M
Decrease in accounts payable and other liabilities 315.2M
Net cash provided by operating activities 1.51B
CASH FLOWS FROM INVESTING ACTIVITIES:
Movements in restricted cash 68.3M
Purchases of subsidiary undertakings, net of cash acquired -17.48B
Purchases of non-current investments -402.5M
Purchases of property, plant and equipment ("PP&E")
Purchases of intangible assets
Proceeds from disposal of non-current investments, PP&E and product rights 600K
Returns of equity investments and proceeds from short term investments
Net cash used in investing activities -17.81B
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from drawings of revolving credit facility 31.74B
Repayment of debt acquired with ABH -14.63B
Payment under building finance obligation
Extinguishment of building finance obligation
Tax benefit of stock based compensation
Proceeds from exercise of options 98.9M
Payment of dividend -130.2M
Payments to acquire shares by ESOT
Net cash used in financing activities 16.9B
Net (decrease)/increase in cash and cash equivalents 593.1M
Effect of foreign exchange rate changes on cash and cash equivalents -2.2M
Cash and cash equivalents at beginning of period 135.5M
Cash and cash equivalents at end of period 728.6M
Supplemental information associated with continuing operations:
Interest paid 223.4M
Income taxes paid 355.8M
Non cash investing and financing activities:
Equity in Vertex Pharmaceuticals, Inc. ("Vertex") received as part consideration for disposal of non-current investment